NASDAQ: NRSN

Business news, market intelligence, and global industry analysis.

The Latest

Four-decade-first: Lok Sabha votes down no-confidence motion against Speaker Om Birla

Representative image illustrating an advanced AI system operating software autonomously, reflecting the Macrohard project unveiled by Tesla, Inc. and xAI, which Elon Musk claims could replicate the full operational functions of software companies using agentic artificial intelligence.

Macrohard : The AI project Musk says no other company can do yet, and what that claim actually means

United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF

Representative image illustrating a drone flying over California as reports reveal that Iran allegedly considered a surprise drone strike on targets in the state, according to a Federal Bureau of Investigation intelligence bulletin disclosed during the ongoing United States–Iran conflict.

Iran planned surprise drone strike on California, FBI bulletin reveals

NeuroSense Therapeutics (NASDAQ: NRSN) gets FDA nod for pivotal ALS trial: Is PrimeC nearing commercial breakthrough?

NeuroSense gains FDA clearance for Phase 3 ALS trial of PrimeC, with patient enrollment and global execution plans underway. Find out what comes next.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 24, 2025